Benefits of Our Solutions


The benefits of implementing our solutions

Our solutions are designed by clinicians working in their expert fields, and tested in the real environment before they are ready to be released. The evaluation process is based on scientific methods and in most cases the results can be found in peer-reviewed journals.

This rigorous process ensures that our solutions are usable and effective in terms of costs and clinical outcomes.

The following benefits and publications are a testament to our academic standing in antimicrobial stewardship, and demonstrate the rigor that goes into developing our tools.

  • A 5-year interrupted time series study conducted across five hospitals in New South Wales found that the implementation of Guidance as a centrally-deployed solution for multisite AMS led to the following benefits:
    • Antimicrobials targeted for increased use rose from 223 to 293 defined daily doses (DDDs)/1000 occupied bed days (OBDs)/month (+32%, < 0.01). Conversely, antimicrobials targeted for decreased use fell from 254 to 196 DDDs/1000 OBDs/month (-23%; < 0.01). 
    • Antimicrobial costs decreased (-AUD$64551/month; < 0.01).
    • HCA-CDI rates decreased post-intervention (-0.2 cases/10 000 OBDs/month; < 0.01).1 
  • A 7-year interrupted time series study conducted at The Royal Melbourne Hospital found that the gradients in the use of restricted antibiotics including:
    • 3rd and 4th generation cephalosporins (+0.52, -0.05, -0.39; P < 0.01);
    • glycopeptides (+0.27, -0.53; P = 0.09);
    • carbapenems (+0.12, -0.24; P = 0.21);
    • aminoglycosides (+0.15, -0.27; P < 0.01); and
    • quinolones (+0.76, +0.11; P = 0.08)
all fell after Guidance was implemented. Trends in increased susceptibility of Staphylococcus aureus to methicillin and improved susceptibility of Pseudomonas spp. to many antibiotics were observed.2
  • The deployment of Guidance associated with an early improvement in antibiotic prescribing practices to treat pneumonia which was greater than the changes seen with academic detailing.3
  • The introduction of an antimicrobial stewardship program with Guidance at its core to triage patients for post prescription review resulted in an immediate reduction in broad spectrum antimicrobial use.4
  • Antibiotic susceptibility patterns of ICU Gram-negative isolates including Pseudomonas improved, over a 5 year period following a significant reduction in broad-spectrum antibiotic consumption after the introduction of Guidance.5
  • A healthcare network comprising South Eastern Sydney LHD, Illawarra Shoalhaven LHD and Sydney Children’s Network Randwick Campus (NSW) reported savings of $1 million annualised for 2013 in drug expenditure, 8 months after Guidance was implemented.6

  1. Bond, SE, Chubaty, AJ, Adhikari, S, Miyakis, S, Boutlis, CS, Yeo, WW, ... & Li-Yan Hui, S 2017, 'Outcomes of multisite antimicrobial stewardship programme implementation with a shared clinical decision support system', J Antimicrob Chemother, 72(7): 2110-2118.
  2. Buising KL, Thursky KA, Robertson MB, Black JF, Street AC, Richards MJ, Brown GV 2008, ‘Electronic antibiotic stewardship--reduced consumption of broad-spectrum antibiotics using a computerized antimicrobial approval system in a hospital setting’, J Antimicrob Chemother, 62(3):608-16.
  3. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV 2008, ‘Improving antibiotic prescribing for adults with community acquired pneumonia: Does a computerised decision support system achieve more than academic detailing alone? A time series analysis’, BMC Med Inform Decis Mak, 31:8-35. 
  4. Cairns KA, Jenney AWJ, Abbott I, Skinner MJ, Doyle JS, Dooley MJ, Cheng AC 2013, ‘Prescribing trends before and after implementation of an antimicrobial stewardship program’, Med J Aust,198:262-266.
  5. Yong MK, Buising KL, Cheng AC, Thursky KA 2010, ‘Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system’, J Antimicrob Chemother, 65(5):1062-9.
  6. Thompson, J and Subhag, A 2013, ‘Multisite implementation of an electronic antimicrobial approval system’.Proceedings of the Australian Society of Antimicrobials Conference, Feb; pp3.4. Available from: ASA Portal:Antimicrobials 2013



Share by: